Daiichi Sankyo Maps Plans To Extend Life Of Azor Beyond Patent Death
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to change its recipe for Azor (olmesartan) for treating high blood pressure so the drug can stay on the market for other uses beyond its 2016 U.S. patent expiration